Title |
Liposarcoma: molecular targets and therapeutic implications
|
---|---|
Published in |
Cellular and Molecular Life Sciences, May 2016
|
DOI | 10.1007/s00018-016-2266-2 |
Pubmed ID | |
Authors |
Kate Lynn J. Bill, Lucia Casadei, Bethany C. Prudner, Hans Iwenofu, Anne M. Strohecker, Raphael E. Pollock |
Abstract |
Liposarcoma (LPS) is the most common soft tissue sarcoma and accounts for approximately 20 % of all adult sarcomas. Current treatment modalities (surgery, chemotherapy, and radiotherapy) all have limitations; therefore, molecularly driven studies are needed to improve the identification and increased understanding of genetic and epigenetic deregulations in LPS if we are to successfully target specific tumorigenic drivers. It can be anticipated that such biology-driven therapeutics will improve treatments by selectively deleting cancer cells while sparing normal tissues. This review will focus on several therapeutically actionable molecular markers identified in well-differentiated LPS and dedifferentiated LPS, highlighting their potential clinical applicability. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 1% |
Unknown | 76 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Postgraduate | 27 | 35% |
Student > Ph. D. Student | 11 | 14% |
Student > Bachelor | 10 | 13% |
Researcher | 4 | 5% |
Student > Master | 4 | 5% |
Other | 8 | 10% |
Unknown | 13 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 35 | 45% |
Agricultural and Biological Sciences | 12 | 16% |
Medicine and Dentistry | 11 | 14% |
Engineering | 2 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 1% |
Other | 1 | 1% |
Unknown | 15 | 19% |